Chinese Firms Bag Most Latest Volume-Based Purchasing Wins
Domestics Favored Over Multinationals?
Domestic companies have won most of the bids in China's latest government procurement round for 62 drugs, marking an end to the previous dominance of off-patent products from multinationals.
You may also be interested in...
The value-based procurement scheme in China is about to be implemented on insulin products and while most of Novo Nordisk's therapies were included in the tender, price cuts are going to impact global sales growth by 3% next year.
China has signaled that it will offer a more level playing field to foreign players as part of a bid to join a major regional trade pact but some see the gesture as offering little real relief and high hurdles remain.
Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.